Frédéric M. Chanson

Phage Pharmaceuticals, Inc. manufactures therapeutic protein which makes use of a proprietary production method that improves upon well-established approaches for the manufacture of proteins and results in the production of simple, properly folded therapeutic proteins at high yields. The company was founded in 1998 and is headquartered in San Diego, CA.

FirmInvest AG is an independent asset manager based in Zurich, Switzerland. With a focus on trust, integrity, and independence, FirmInvest implements fully personalized investment solutions based on clients' specific needs and requirements. The Swiss company's services include asset management, active advisory, and family office services. With a team of experienced partners, FirmInvest offers expertise in equity and high-yield fixed income investing, as well as biotech investments. FirmInvest AG also provides additional solutions such as asset and portfolio consolidations, financial consulting, and succession planning. Founded in 1995 by Fabio L. B. Pelli and Frédéric M. Chanson, the company develops custom-made investment strategies for Swiss and international clients.

Coresystems AG engages in the development of applications and mobility and cloud solutions in order to make business processes and customer service more efficient. It specializes in SAP Business One and SAP Field Service solutions. The firm also provides consulting, training, and support services. The company was founded by Manuel Grenacher and is headquartered in Windisch, Switzerland.

Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.